NRAS and metastatic neoplasm: When evaluating the mutational frequencies between alterations in definitively L/LR (specimen site designated as “breast”) versus metastatic specimens, there were significantly more frequent mutations identified in NRAS (4.4% vs 18.2%, P = .022) and TERT (63.2% vs 83.8%, P = .037) in the metastatic tumors.